|Other names||EDBu; Estradiol dibutanoate; Estradiol 3,17β-dibutanoate|
|Drug class||Estrogen; Estrogen ester|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||412.570 g·mol−1|
|3D model (JSmol)|
Estradiol dibutyrate (EDBu), or estradiol dibutanoate, is an estrogen medication and an estrogen ester – specifically, a diester of estradiol – which is no longer used. It was a component of Triormon Depositum, a combination formulation of estradiol dibutyrate, testosterone caproate, and hydroxyprogesterone heptanoate which was developed in the 1950s.
- List of estrogen esters § Estradiol esters
- Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate
- Cacciari P (August 1960). "[Experimental research on estradiol dibutyrate]". Minerva Ginecol (in Italian). 12: 788–9. PMID 13689684.
- Ermiglia, G; Valli, P (1957). "Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect". Quaderni Clin. Ostet. E Ginecol. 12: 284–93.
Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.